CS
DSGN icon

Candriam SCA’s Design Therapeutics DSGN Stock Holding History

Candriam SCA’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-225,000
Closed -$596K – 706
2023
Q4 		$596K Hold
225,000
– – ﹤0.01% 645
2023
Q3 		$531K Buy
225,000
+40,000
+22% +$187K ﹤0.01% 620
2023
Q2 		$1.17M Buy
+185,000
New +$1.13M 0.01% 587

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's DSGN Position: Q1 2024 in Review

Candriam SCA sold out of Design Therapeutics (DSGN) in Q1 2024, closing a stake of 225,000 shares — an estimated $596K sold.

Candriam SCA first reported a position in DSGN in Q2 2023 and held it in 3 quarters. The position peaked at $1.17M in Q2 2023. 93 funds tracked by Wall St. Rank hold DSGN as of Q1 2024.

  • Candriam SCA reported no remaining Design Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Candriam SCA sold 225,000 Design Therapeutics shares in Q1 2024, an estimated $596K.
  • Candriam SCA first reported a position in Design Therapeutics in Q2 2023 and held it in 3 quarters.
  • Candriam SCA's Design Therapeutics position peaked at $1.17M in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.